Hexarelin

Mechanism of action

Hexarelin is a 6-amino-acid synthetic peptide (His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2) developed by Mediolanum Farmaceutici as an analogue of GHRP-6 with structural modifications designed to enhance GH-releasing potency. The two key modifications are 2-methylation of D-tryptophan at position 2 (improving GHSR-1a binding affinity) and C-terminal amidation (extending metabolic stability against carboxypeptidase degradation). The molecular weight of 887 Da and pentapeptide-equivalent size place hexarelin alongside ipamorelin and GHRP-2 as the small, GHSR-targeted GHRPs. The primary mechanism of action is ghrelin-receptor (GHSR-1a) agonism on anterior-pituitary somatotrophs — identical to the other GHRP-class compounds. Receptor activation triggers Gαq/11-coupled signalling through phospholipase Cβ, generating inositol trisphosphate (IP₃) that releases intracellular calcium and diacylglycerol that activates protein kinase C. The calcium and PKC signals converge on growth-hormone vesicle exocytosis, producing the pulsatile GH release that defines GHRP-class pharmacology. The pharmacological distinguishing feature of hexarelin within the GHRP class is its acute GH-releasing capacity. At saturating intravenous doses, hexarelin produces materially larger acute GH peaks than ipamorelin, GHRP-2, or GHRP-6 — establishing hexarelin as the most potent acute GH-releasing GHRP. The molecular basis for this enhanced potency is incompletely characterised but appears to relate to receptor-binding kinetics and possibly to additional weak engagement of secondary signalling pathways. A critical mechanistic feature unique to hexarelin among the GHRPs is direct binding to the CD36 scavenger receptor on cardiomyocytes — a transmembrane glycoprotein with broad ligand specificity including modified low-density lipoprotein, long-chain fatty acids, and several peptide ligands. CD36 binding by hexarelin produces cardiac-conditioning effects mechanistically distinct from the GHSR-1a-mediated pituitary GH-release pathway: reduced ischaemia-reperfusion injury in cardiac models, attenuation of post-infarct ventricular remodelling, and modest direct cardioprotective effects. These cardiac effects have been demonstrated in multiple rodent and large-animal cardiac-injury models, generating substantial cardiology research interest in hexarelin distinct from its GH-axis pharmacology. GH-axis pharmacology of hexarelin has two notable practical limitations relative to other GHRPs. First, the larger acute GH peak is offset by notable cortisol and prolactin spillover — though smaller than GHRP-6, hexarelin does not match ipamorelin's GHRP-class selectivity. Second, hexarelin produces marked GH-axis desensitisation with chronic dosing — sustained somatotroph GHSR-1a activation downregulates receptor expression and produces progressive attenuation of GH release across days to weeks of repeated dosing. This desensitisation is more pronounced than with ipamorelin, GHRP-2, or even GHRP-6, limiting chronic-dosing applications and making hexarelin pharmacologically better suited to acute pharmacological challenge (single-dose GH-stimulation testing) than chronic GH-axis modulation. Downstream of pituitary GH release, hexarelin produces canonical IGF-1 elevation through the GH-receptor/JAK2/STAT5 cascade. Combined administration with a GHRH analogue (sermorelin, CJC-1295 no-DAC) produces synergistic GH pulses through dual-pathway activation, though the chronic-dosing desensitisation reduces the practical utility of long-term hexarelin combination protocols relative to ipamorelin.

Hexarelin binds the CD36 scavenger receptor on cardiomyocytes — a mechanism unique within the GHRP class — producing cardioprotective effects in cardiac ischaemia-reperfusion and post-infarct remodelling models distinct from its GHSR-1a-mediated GH-axis pharmacology (Bodart et al., Circ Res, 2002). The cardiac CD36 mechanism represents the principal scientific legacy of hexarelin and an unexpected mechanistic link between a GH-secretagogue peptide and direct cardiac signalling.

— Notable finding

Research history

Hexarelin was developed by Mediolanum Farmaceutici (Milan, Italy) in the early 1990s as an enhanced analogue of GHRP-6, the founding GHRP-class compound originally synthesised by Cyril Bowers and colleagues. The systematic medicinal chemistry programme that produced hexarelin paralleled similar efforts by Novo Nordisk (ipamorelin) and Kaken Pharmaceutical (GHRP-2). The compound entered Phase I clinical evaluation in the mid-1990s, with Italian and European research groups producing a substantial body of GH-axis pharmacology characterisation across the late 1990s and early 2000s. The initial clinical-development focus was paediatric growth-hormone deficiency, paralleling the Geref (sermorelin) and recombinant somatropin indications. Phase II programmes explored adult GH-deficiency replacement and short stature applications. The development trajectory was complicated by the GH-axis desensitisation observed with chronic dosing — a pharmacological liability that disadvantaged hexarelin against alternative GHRPs in chronic-replacement settings. The compound did not progress to registration in any jurisdiction. Alongside the GH-axis programme, Mediolanum-supported and academic cardiology research characterised hexarelin's cardiac CD36 receptor binding and the resulting cardioprotective effects in pre-clinical ischaemia-reperfusion and post-infarct models. This cardiac-research stream has generated a substantial publication record and represents the principal scientific legacy of hexarelin — establishing the unexpected mechanistic link between a GH-secretagogue peptide and direct cardiac CD36 signalling. Clinical translation of the cardiac findings has not occurred. Hexarelin entered the research-chemical market in the late 2000s, achieving moderate research-community uptake — substantially less than CJC-1295 + ipamorelin combinations but with sustained interest among researchers specifically targeting maximum acute GH-releasing capacity or the cardiac CD36 mechanism. The chronic-dosing desensitisation has constrained research-chemical-community use, since the standard GH-axis protocols favour compounds that sustain efficacy across daily-to-weekly dosing windows. In 2025, hexarelin holds no marketing authorisation in any jurisdiction and is available principally through research-chemical suppliers. Active clinical development is absent.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Acute safety data for hexarelin come primarily from the 1990s Mediolanum clinical-development programme and subsequent academic research. The acute adverse-event profile includes mild transient flushing and warmth following IV bolus administration, occasional mild headache, and infrequent transient hypotension at higher IV doses. Subcutaneous administration produces a milder acute profile with predominantly injection-site reactions. The principal pharmacodynamic safety considerations relate to the GHRP-class GH-axis effects — cortisol and prolactin elevation. Hexarelin produces measurable but moderate cortisol elevation (2- to 3-fold transient rises at saturating doses), substantially smaller than GHRP-6 (3- to 4-fold rises) but materially larger than ipamorelin (no measurable cortisol effect). Prolactin elevation is similarly intermediate. These off-target effects do not produce clinically significant adverse consequences from acute single-dose administration but should be considered in research where adrenal-axis or prolactin endpoints are being measured. Chronic-dosing safety experience is limited but the principal pharmacological concern is the GH-axis desensitisation with sustained somatotroph GHSR-1a activation. Repeated daily dosing across days-to-weeks produces progressive attenuation of GH release — a tachyphylactic response that limits practical chronic-replacement utility. Theoretical concerns about chronic GH/IGF-1 elevation parallel other GH-axis peptides: oncogenic risk through IGF-1R activation, insulin resistance, and diabetic retinopathy progression. The direct cardiac CD36 receptor binding raises theoretical cardiovascular considerations specific to hexarelin. Acute cardiovascular effects in published trials have been favourable (cardioprotective in ischaemia models), but the chronic effects of pharmacological CD36 modulation are incompletely characterised. Researchers using hexarelin in cardiac-disease populations or models should monitor cardiac endpoints accordingly. Hexarelin's hexapeptide structure (887 Da) with non-standard amino acids carries low immunogenicity risk. Anti-drug antibodies have not been a significant issue in published data. Sterility and endotoxin content of research-chemical-grade preparations remain the dominant practical safety variables. No serious immediate adverse events (anaphylaxis, severe hypotension, cardiac events) have been documented at research-protocol doses.

UK regulatory status

Hexarelin is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Hexarelin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone secretagogue. Athletes subject to anti-doping testing should treat hexarelin and all GHRP-class peptides as prohibited both in-competition and out-of-competition regardless of claimed research purpose. MHRA enforcement actions concerning hexarelin supply specifically have not been published in the public domain. Generic warnings on unlicensed peptide supply for human use apply. Research-grade hexarelin for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA (Animals (Scientific Procedures) Act 1986), hexarelin work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

Frequently asked questions